therapeutics

Waters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics

Headlines: Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1 Enables accurate analysis of protein complexes,…

3 months ago

Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?

Carlsbad, CA, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the official launch…

3 months ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinsons Disease

Event to be held October 14th at 4 p.m. EST October 09, 2025 07:00 ET  | Source: Gain Therapeutics, Inc.…

4 months ago

Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community

October 09, 2025 07:00 ET  | Source: Axsome Therapeutics, Inc. NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics,…

4 months ago

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

October 05, 2025 09:00 ET  | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…

4 months ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025 16:01 ET  | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics,…

4 months ago

XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ:…

4 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

September 20, 2025 11:00 ET  | Source: C4 Therapeutics, Inc. Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response…

4 months ago

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a…

4 months ago

Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…

4 months ago